Catrin Lutz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Catrin Lutz has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Jos Jonkers
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
55 shared publications - Bjørn Siteur
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
54 shared publications - Jinhyuk Bhin
Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea
54 shared publications - Marieke van de Ven
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
54 shared publications - Ji-Ying Song
Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
39 shared publications - Natalie Proost
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
39 shared publications
Latest Publications
- Open Access
SMIM1 drives an alternative iron uptake pathway
Iron is essential for numerous biological processes, and its abundance is critical in human cells to prevent anemia or toxic overload 1,2 . Although transferrin receptor-mediated iron uptake is the canonical route 3–5 , human cells also possess an unstudied alternative pathway. To reveal this missing mechanism, we developed a large-scale, gain-of-function approach to assign genes to a catalogue of quantitative cellular traits. Applying this genetic strategy, we identified SMIM1, the antigen responsible for the rare Vel blood group and a transmembrane protein with unknown function, as a key regulator of iron homeostasis. We found that SMIM1 expression completely suppresses the iron deficiency caused by transferrin receptor loss. Mechanistically, SMIM1 mediates iron uptake through clathrin-dependent endocytosis of hemoglobin (Hb). SMIM1 directly binds Hb via its extracellular HKCK motif, leading to its transport to lysosomes and subsequent iron release. In the human population, genetic variants in SMIM1 influence Hb levels and erythrocyte traits. SMIM1-deficient mice display iron deficiency in early erythroid precursors in response to erythropoietic stress, underscoring the physiological relevance of this process.
Open AccessSMIM1 drives an alternative iron uptake pathway
Iron is essential for numerous biological processes, and its abundance is critical in human cells to prevent anemia or toxic overload 1,2 . Although transferrin receptor-mediated iron uptake is the canonical route 3–5 , human cells also possess an unstudied alternative pathway. To reveal this missing mechanism, we developed a large-scale, gain-of-function approach to assign genes to a catalogue of quantitative cellular traits. Applying this genetic strategy, we identified SMIM1, the antigen responsible for the rare Vel blood group and a transmembrane protein with unknown function, as a key regulator of iron homeostasis. We found that SMIM1 expression completely suppresses the iron deficiency caused by transferrin receptor loss. Mechanistically, SMIM1 mediates iron uptake through clathrin-dependent endocytosis of hemoglobin (Hb). SMIM1 directly binds Hb via its extracellular HKCK motif, leading to its transport to lysosomes and subsequent iron release. In the human population, genetic variants in SMIM1 influence Hb levels and erythrocyte traits. SMIM1-deficient mice display iron deficiency in early erythroid precursors in response to erythropoietic stress, underscoring the physiological relevance of this process.
- Open Access
- 6 October 2026
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 54 (10) , 1419-1430
Genes, fuel, and fate in lung cancer
Cellular plasticity is a central feature of malignant progression, allowing tumour cells to change identity during tumour evolution, therapeutic adaptation, and metastatic dissemination. This issue is especially acute in lung cancer, where the respiratory epithelium is intrinsically permissive to cell-state change. Genetic lesions, chromatin regulation, and metabolic adaptation are often framed as parallel determinants of lineage plasticity. Emerging evidence instead points to functional coupling across these layers. Oncogenic alterations can weaken lineage fidelity and open alternative trajectories, chromatin regulators can stabilise transitional states and enforce new transcriptional programmes, and metabolic rewiring can supply the biochemical conditions required for these states to emerge and persist. Microenvironmental cues further influence which trajectories are selected and maintained. Here, we discuss the genetic, epigenetic, and metabolic determinants of lineage plasticity in lung cancer, focusing on the points at which they intersect. We propose that plasticity is most usefully understood as a coupled regulatory state, arising from the interaction between oncogenic context, chromatin control, and metabolic support. Defining how these dependencies arise and become functionally coupled within high-plasticity transitional states should help identify points at which lineage switching can be intercepted before alternative lineage programmes are stabilised.
- 6 October 2026
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 54 (10) , 1419-1430
Open AccessGenes, fuel, and fate in lung cancer
Cellular plasticity is a central feature of malignant progression, allowing tumour cells to change identity during tumour evolution, therapeutic adaptation, and metastatic dissemination. This issue is especially acute in lung cancer, where the respiratory epithelium is intrinsically permissive to cell-state change. Genetic lesions, chromatin regulation, and metabolic adaptation are often framed as parallel determinants of lineage plasticity. Emerging evidence instead points to functional coupling across these layers. Oncogenic alterations can weaken lineage fidelity and open alternative trajectories, chromatin regulators can stabilise transitional states and enforce new transcriptional programmes, and metabolic rewiring can supply the biochemical conditions required for these states to emerge and persist. Microenvironmental cues further influence which trajectories are selected and maintained. Here, we discuss the genetic, epigenetic, and metabolic determinants of lineage plasticity in lung cancer, focusing on the points at which they intersect. We propose that plasticity is most usefully understood as a coupled regulatory state, arising from the interaction between oncogenic context, chromatin control, and metabolic support. Defining how these dependencies arise and become functionally coupled within high-plasticity transitional states should help identify points at which lineage switching can be intercepted before alternative lineage programmes are stabilised.
- 18 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (841) , eads9088
Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies
Targeted therapies are important for invasive breast cancer (IBC) treatment but are generally not standard of care in the neoadjuvant setting. To identify therapies with the potential to improve neoadjuvant treatment response, it is essential to develop patient-derived preclinical models that faithfully reflect the diversity of primary IBC subtypes in patients. Here, we generated and characterized a large-scale cohort of 60 mouse-intraductal patient-derived xenograft (MIND-PDX) models representing all subtypes of primary IBC, as well as seven matched PDX-derived organoids. We showed that our IBC-MIND cohort can serve as a platform for preclinical evaluation of experimental neoadjuvant treatments. For triple-negative IBC, we demonstrated that neoadjuvant treatment does not benefit from addition of a PARP inhibitor, whereas for estrogen receptor–positive IBC, the combination of a CDK4/6 inhibitor and fulvestrant improved neoadjuvant treatment response. Our work provides a valuable resource of primary IBC models to study breast cancer biology and develop neoadjuvant treatments.
- 18 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (841) , eads9088
Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies
Targeted therapies are important for invasive breast cancer (IBC) treatment but are generally not standard of care in the neoadjuvant setting. To identify therapies with the potential to improve neoadjuvant treatment response, it is essential to develop patient-derived preclinical models that faithfully reflect the diversity of primary IBC subtypes in patients. Here, we generated and characterized a large-scale cohort of 60 mouse-intraductal patient-derived xenograft (MIND-PDX) models representing all subtypes of primary IBC, as well as seven matched PDX-derived organoids. We showed that our IBC-MIND cohort can serve as a platform for preclinical evaluation of experimental neoadjuvant treatments. For triple-negative IBC, we demonstrated that neoadjuvant treatment does not benefit from addition of a PARP inhibitor, whereas for estrogen receptor–positive IBC, the combination of a CDK4/6 inhibitor and fulvestrant improved neoadjuvant treatment response. Our work provides a valuable resource of primary IBC models to study breast cancer biology and develop neoadjuvant treatments.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-CC2-Pro construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-CC2-Pro construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S8 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tnip2 construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S8 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tnip2 construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
HALO-FGFR3 expression in NMuMG cells and FACS gating strategy used for the SPIDA assay
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
HALO-FGFR3 expression in NMuMG cells and FACS gating strategy used for the SPIDA assay
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
List of metastatic solid tumor samples harboring structural rearrangements affecting FGFR3 identified in the HMF cohort
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
List of metastatic solid tumor samples harboring structural rearrangements affecting FGFR3 identified in the HMF cohort
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Evaluation of tumor growth, drug exposure, and adaptive resistance emergence following fexagratinib treatment in Fgfr3ΔE18-Tacc3-driven mouse mammary tumors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Evaluation of tumor growth, drug exposure, and adaptive resistance emergence following fexagratinib treatment in Fgfr3ΔE18-Tacc3-driven mouse mammary tumors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S5 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-L772A/L773A construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S5 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-L772A/L773A construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Overview of FGFR3-truncating mutations in the FMI cohort and junction read ratios in HMF RNA-seq profiles
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Overview of FGFR3-truncating mutations in the FMI cohort and junction read ratios in HMF RNA-seq profiles